文献詳細
特集 複合免疫療法とは何か? 腎細胞癌の最新治療から学ぶ
〈腎細胞癌における複合免疫療法〉
文献概要
▶ポイント
・ニボルマブ+イピリムマブ併用療法は転移性腎細胞癌に対する一次治療として,IMDC分類の中間および高リスク症例に適応がある.
・CheckMate214試験の長期観察データにおいて,スニチニブと比較して全生存期間(OS)の延長効果を持続して認めている.
・複合免疫療法の薬剤選択には,宿主側の免疫状態と腫瘍側の生物学的特徴を明らかにする必要がある.
・ニボルマブ+イピリムマブ併用療法は転移性腎細胞癌に対する一次治療として,IMDC分類の中間および高リスク症例に適応がある.
・CheckMate214試験の長期観察データにおいて,スニチニブと比較して全生存期間(OS)の延長効果を持続して認めている.
・複合免疫療法の薬剤選択には,宿主側の免疫状態と腫瘍側の生物学的特徴を明らかにする必要がある.
参考文献
1) 山下万貴子, 他 : 免疫チェックポイント関連薬剤. In : 秋山 徹, 他 (編) : 決定版阻害剤・活性化剤ハンドブック. 羊土社, 東京, 2019
2) Peggs KS, et al : Blockade of CTLA-4 on Both Effector and Regulatory T Cell Compartments Contributes to the Antitumor Activity of Anti-CTLA-4 Antibodies. J Exp Med 206 : 1717-1725, 2009
3) Simpson TR, et al : Fc-dependent Depletion of Tumor-Infiltrating Regulatory T Cells Co-Defines the Efficacy of Anti-CTLA-4 Therapy Against Melanoma. J Exp Med 210 : 1695-1710, 2013
4) Wei SC, et al : Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170 : 1120-1133 e17, 2017
5) Kitano S, et al : Enhancement of Tumor-Reactive Cytotoxic CD4+ T Cell Responses After Ipilimumab Treatment in Four Advanced Melanoma Patients. Cancer Immunol Res 1 : 235-244, 2013
6) Motzer RJ, et al : Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced Renal Cell Carcinoma : Extended Follow-Up of Efficacy and Safety Results from a Randomised, Controlled, Phase 3 Trial. Lancet Oncol 20 : 1370-1385, 2019
7) Ikarashi D, et al : Case of Complete Response to Neoadjuvant Therapy Using Nivolumab in a Patient with Metastatic Renal Cell Carcinoma. Int J Urol 25 : 630-632, 2018
8) Peak TC, et al : Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma. Case Rep Urol 2020 Nov 1 : 8846135, 2020
9) Tanaka N, et al : Effect of Reclassification of the IMDC Model in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy in the First-Line and Second-Line Settings. Urol Oncol 34 : 293.e17-25, 2016
10) Kaneko G, et al : Sub-classification of Patients with Intermediate-risk Metastatic Renal Cell Carcinoma Treated with Targeted Therapy. Jpn J Clin Oncol 49 : 780-785, 2019
11) Escudier B, et al : Efficacy of Nivolumab Plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol 77 : 449-453, 2020
12) Tanaka T, et al : Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Metastatic Renal Cell Carcinoma : A Multicenter Retrospective Study. Int J Urol 27 : 1095-1100, 2020
13) Tannir NM, et al : Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res 27 : 78-86, 2021
14) Ng Tang D, et al : Increased frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. Cancer Immunol Res 1 : 229-234, 2013
掲載誌情報